OS Therapies to develop BlinkBio next-generation Antibody Drug Conjugate (ADC) technology; BlinkBio CEO Colin Goddard joins OS Therapies Board CAMBRIDGE, Md. and LONDON, Aug. 26, 2020 (GLOBE NEWSWIRE) -- OS Therapies, and late-stage clinical research biotechnology company focused on Osteosarcoma and other solid tumors today announced the...